Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CCKBR | P32239 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787100 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL28478851 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL29630317 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL3481444 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760630 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL2215687 | 0.92 | CYP2D6 (0.85) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760541 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL32689432 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL32689431 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760584 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| CN-116059203-A | Autotaxin inhibitors and uses thereof | 赛博治疗有限责任公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| CN-111303148-B | 1-substituted beta-carboline derivatives and application thereof | 南京农业大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| CN-111303148-A | 1-substituted β -carboline derivatives and application thereof | 南京农业大学 | 2020-06-19 | — | — | CN | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | disclosed |
| US-4336260-A | Method and compositions using 1-aryl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid for treating depression | THE DOW CHEMICAL COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | CYP2D6 4809/4885TSHR 4486/4885MAPK1 3087/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | CYP2D6 4041/4885TSHR 3369/4885MAPK1 3648/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | CYP2D6 3664/4885TSHR 4635/4885MAPK1 2584/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | CYP2D6 4147/4885TSHR 4754/4885MAPK1 2450/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | CYP2D6 2555/4885TSHR 2025/4885MAPK1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.